197 related articles for article (PubMed ID: 27699863)
1. Budesonide foam for mild to moderate distal ulcerative colitis: A systematic review and meta-analysis.
Zeng J; Lv L; Mei ZC
J Gastroenterol Hepatol; 2017 Mar; 32(3):558-566. PubMed ID: 27699863
[TBL] [Abstract][Full Text] [Related]
2. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study.
Naganuma M; Aoyama N; Tada T; Kobayashi K; Hirai F; Watanabe K; Watanabe M; Hibi T
J Gastroenterol; 2018 Apr; 53(4):494-506. PubMed ID: 28779419
[TBL] [Abstract][Full Text] [Related]
3. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.
Naganuma M; Aoyama N; Suzuki Y; Nishino H; Kobayashi K; Hirai F; Watanabe K; Hibi T
J Crohns Colitis; 2016 Jul; 10(7):828-36. PubMed ID: 26577683
[TBL] [Abstract][Full Text] [Related]
4. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis.
Sandborn WJ; Bosworth B; Zakko S; Gordon GL; Clemmons DR; Golden PL; Rolleri RL; Yu J; Barrett AC; Bortey E; Paterson C; Forbes WP
Gastroenterology; 2015 Apr; 148(4):740-750.e2. PubMed ID: 25644096
[TBL] [Abstract][Full Text] [Related]
5. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Feagan BG; Macdonald JK
Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
[TBL] [Abstract][Full Text] [Related]
6. Oral budesonide for induction of remission in ulcerative colitis.
Sherlock ME; Seow CH; Steinhart AH; Griffiths AM
Cochrane Database Syst Rev; 2010 Oct; (10):CD007698. PubMed ID: 20927762
[TBL] [Abstract][Full Text] [Related]
7. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis.
Rubin DT; Sandborn WJ; Bosworth B; Zakko S; Gordon GL; Sale ME; Rolleri RL; Golden PL; Barrett AC; Bortey E; Forbes WP
Dig Dis Sci; 2015 Nov; 60(11):3408-17. PubMed ID: 26386854
[TBL] [Abstract][Full Text] [Related]
8. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Bosworth BP; Sandborn WJ; Rubin DT; Harper JR
Inflamm Bowel Dis; 2016 Aug; 22(8):1881-6. PubMed ID: 27416045
[TBL] [Abstract][Full Text] [Related]
9. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Marshall JK; Thabane M; Steinhart AH; Newman JR; Anand A; Irvine EJ
Cochrane Database Syst Rev; 2010 Jan; (1):CD004115. PubMed ID: 20091560
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis.
Ford AC; Bernstein CN; Khan KJ; Abreu MT; Marshall JK; Talley NJ; Moayyedi P
Am J Gastroenterol; 2011 Apr; 106(4):590-9; quiz 600. PubMed ID: 21407179
[TBL] [Abstract][Full Text] [Related]
11. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.
Bonovas S; Nikolopoulos GK; Piovani D; González-Lorenzo M; Pantavou K; Lytras T; Peyrin-Biroulet L; Danese S
Br J Clin Pharmacol; 2019 Oct; 85(10):2244-2254. PubMed ID: 31269287
[TBL] [Abstract][Full Text] [Related]
12. Vedolizumab for induction and maintenance of remission in ulcerative colitis.
Bickston SJ; Behm BW; Tsoulis DJ; Cheng J; MacDonald JK; Khanna R; Feagan BG
Cochrane Database Syst Rev; 2014 Aug; (8):CD007571. PubMed ID: 25105240
[TBL] [Abstract][Full Text] [Related]
13. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
Sandborn WJ; Danese S; D'Haens G; Moro L; Jones R; Bagin R; Huang M; David Ballard E; Masure J; Travis S
Aliment Pharmacol Ther; 2015 Mar; 41(5):409-18. PubMed ID: 25588902
[TBL] [Abstract][Full Text] [Related]
14. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
Sandborn WJ; Travis S; Moro L; Jones R; Gautille T; Bagin R; Huang M; Yeung P; Ballard ED
Gastroenterology; 2012 Nov; 143(5):1218-1226.e2. PubMed ID: 22892337
[TBL] [Abstract][Full Text] [Related]
15. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
Rubin DT; Cohen RD; Sandborn WJ; Lichtenstein GR; Axler J; Riddell RH; Zhu C; Barrett AC; Bortey E; Forbes WP
J Crohns Colitis; 2017 Jul; 11(7):785-791. PubMed ID: 28333362
[TBL] [Abstract][Full Text] [Related]
16. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
Travis SP; Danese S; Kupcinskas L; Alexeeva O; D'Haens G; Gibson PR; Moro L; Jones R; Ballard ED; Masure J; Rossini M; Sandborn WJ
Gut; 2014 Mar; 63(3):433-41. PubMed ID: 23436336
[TBL] [Abstract][Full Text] [Related]
17. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands.
Gherardi A; Roze S; Kuijvenhoven J; Ghatnekar O; Yip Sonderegger YL
J Med Econ; 2018 Sep; 21(9):869-877. PubMed ID: 29857775
[TBL] [Abstract][Full Text] [Related]
18. Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
Kruis W; Siegmund B; Lesniakowski K; Simanenkov V; Khimion L; Sobon M; Delmans G; Maksyashina SV; Sablin OA; Pokrotnieks J; Mostovoy Y; Datsenko O; Abdulkhakov S; Dorofeyev A; Levchenko O; Alexeeva O; Andreev P; Kolesnik IP; Mihaly E; Abrahamovych O; Baluta M; Kharchenko N; Viacheslav N; Uspenskiy Y; Vieth M; Mohrbacher R; Mueller R; Greinwald R
J Crohns Colitis; 2022 Nov; 16(11):1714-1724. PubMed ID: 35709376
[TBL] [Abstract][Full Text] [Related]
19. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis.
Gross V; Bar-Meir S; Lavy A; Mickisch O; Tulassay Z; Pronai L; Kupcinskas L; Kiudelis G; Pokrotnieks J; Kovács A; Faszczyk M; Razbadauskas A; Margus B; Stolte M; Müller R; Greinwald R;
Aliment Pharmacol Ther; 2006 Jan; 23(2):303-12. PubMed ID: 16393311
[TBL] [Abstract][Full Text] [Related]
20. Controlled, open, randomized multicenter trial comparing the effects of treatment on quality of life, safety and efficacy of budesonide foam and betamethasone enemas in patients with active distal ulcerative colitis.
Hammond A; Andus T; Gierend M; Ecker KW; Scholmerich J; Herfarth H;
Hepatogastroenterology; 2004; 51(59):1345-9. PubMed ID: 15362749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]